DOVIPA, a Phase II Study Evaluating Efficacy and Safety of DOstarlimab and Oral VItamin D3 with Folinic Acid, 5FU, Irinotecan Plus Oxalipaltin (mFOLFIRINOX) in Non Pretreated Metastatic PAncreatic Cancer
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs Colecalciferol (Primary) ; Dostarlimab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms DOVIPA
- 09 Jan 2025 New trial record